BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Telix to Present ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EAU

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (Clinic...

March 09, 2023 | News

JW Therapeutics Starts Clinical Trial of Carteyva® for High-Risk Large B-Cell Lymphoma

High-risk large B-cell lymphoma includes large B-cell lymphoma with International Prognostic Index (IPI) score ≥3, and high-grade B-cell lymphoma (HGBL)...

March 09, 2023 | News

Hummingbird Bioscience licenses Cancer Research UK's clinical trial results to support HMBD-001 development.

The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investi...

March 06, 2023 | News

Harbour BioMed's Batoclimab Shows Positive Results in Phase III Trial for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...

March 06, 2023 | News

C2i Genomics Expands to Japan, Announces Collab with Riken Genesis

The collaboration will expand C2i’s global reach and bring MRD cancer monitoring capabilities for solid tumors to Japan C2i Genomics...

March 03, 2023 | News

Celebrating International Women's Day: Recognizing 12 Leading Women in Clinical Trials in APAC

As BioPharma APAC celebrates International Women's Day on March 8, it's time to recognize the remarkable contributions of women in clinical trials. These w...

March 03, 2023 | News

BRIM appoints Andrew Lin as Chairman and Dr. Wen Chyi Shyu as CEO, secures $18M in Series E funding, and advances clinical trials for Dry Eye Disease and Neurotrophic Keratitis treatments

What led to the decision to elect Andrew Lin as the new Chairman of the Board, and how do you believe he will contribute to BRIM's continued succ...

March 01, 2023 | Opinion

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

Primary hepatic cancer is a common malignant tumor of the digestive system worldwide, with high malignancy and hepatic prognosis. As the most common pathol...

March 01, 2023 | News

Veeva Vault EDC Becomes Standard for New Trials in Six of the Top 20 Pharma Companies

Veeva Systems (NYSE: VEEV) today announced increasing adoption of Veeva Vault EDC as leading organizations – including 6 of the ...

February 27, 2023 | News

Precision Medicine Takes Center Stage: Exploring the Innovative Biopharma Industry in Australia and New Zealand

Australia and New Zealand have always been at the forefront of innovation and research in the biopharma industry. The region's strategic location and stron...

February 24, 2023 | News

Keymed and Lepu Biopharma gain global exclusive license for CMG901 from AstraZeneca.

CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors. Preliminary results from the Phase 1 trial indicat...

February 24, 2023 | News

Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA

FP002 is a humanized anti-CD47 IgG4 monoclonal antibody, developed and patented by Fapon Biopharma. It binds strongly to the CD47 protein on the surface of...

February 23, 2023 | News

Neurophth completes Phase III trial enrollment for LHON gene therapy

Neurophth Therapeutics, Inc. ("Neurophth") announced today that the last patient has been enrolled in the Phase III clinical trial for the treatment o...

February 22, 2023 | News

RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore

The clinical trial aims to evaluate three of RVAC's COVID-19 vaccine candidates that include one against the ancestral strain, one against an Omicron strai...

February 21, 2023 | News

Stay Connected